Serum in vivo angiogenic activity and some pro-angiogenic cytokine levels in diabetes mellitus type 2 (DM2) patients with or without background retinopathy

Central-European Journal of Immunology

Volumn 32, Issue 2, 2007, Pages 48-52

  Skopiński, Piotr ^a,b   Szaflik, Jerzy ^b   Partyka, Iwona ^b   Chorostowska Wynimko, Joanna ^c   Duda Krŕol, Barbara ^b   Lipińska, Anna ^d   Sommer, Ewa ^a   Skopińska Rózewska, Ewa ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

^c NATIONAL TUBERCULOSIS AND LUNG DISEASES RESEARCH INSTITUTE   (Poland)

^d Institute of Dentistry   (Poland)

Author keywords

Angiogenesis; Cytokines; DM2 patients; Sera

Indexed keywords

INTERLEUKIN 18; SOMATOMEDIN C; VASCULOTROPIN;

ADULT; AGED; ANIMAL EXPERIMENT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DIABETIC RETINOPATHY; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IN VIVO STUDY; MAJOR CLINICAL STUDY; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOGENESIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RENOVASCULAR DISEASE;

EID: 34249745645     PISSN: 14263912     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Ozaki H, Seo MS, Ozaki K, et al. (2000): Blockade of vascular endothelial cell growth factor receptor signalling is sufficient to completely prevent retinal neovascularization. Am J Pathol 156: 697-707.
2. Denley A, Cosgrove LJ, Booker GW, et al. (2005): Molecular interactions of the IGF system. Cytokine Growth Factor Rev 16: 421-439.
3. Punglia RS, Lu M, Hsu J, et al. (1997): Regulation of vascular endothelial growth factor expression by insulin-like growth factor I. Diabetes 46: 1619-1626.
4. Grant MB, Mames RN, Fitzgerald C, et al. (1993): Insulin-like growth factor I as an angiogenic agent. In vivo and in vitro studies. Ann N Y Acad Sci 692: 230-242.
5. Chantelau E (1998): Evidence that upregulation of serum IGF-1 concentration can trigger acceleration of diabetic retinopathy. Br J Ophthalmol 82: 725-730.
6. Hui W, Rowan AD, Cawston T (2001): Insulin-like growth factor 1 blocks collagen release and down regulates matrix metalloproteinase-1, -3, -8, and -13 mRNA expression in bovine nasal cartilage stimulated with oncostatin M in combination with interleukin 1alpha. Ann Rheum Dis 60: 254-261.
7. Im HJ, Pacione C, Chubinskaya S, et al. (2003): Inhibitory effects of insulin-like growth factor-1 and osteogenic protein-1 on fibronectin fragment- and interleukin-1beta-stimulated matrix metalloproteinase-13 expression in human chondrocytes. J Biol Chem 278: 25386-25394.
8. Pattison ST, Melrose J, Ghosh P, Taylor TK (2001): Regulation of gelatinase-A (MMP-2) production by ovine intervertebral disc nucleus pulposus cells grown in alginate bead culture by Transforming Growth Factor-beta(1) and insulin like growth factor-I. Cell Biol Int 25: 679-689.
9. Kajstura J, Fiordaliso F, Andreoli AM, et al. (2001): IGF-1 overexpression inhibits the development of diabetic cardiomyopathy and angiotensin II- mediated oxidative stress. Diabetes 50: 1414-1421.
10. Skopinski P, Sommer E, Kwiek S, et al. (2001): Angiotensin - converting enzyme (ACE) activity and angiomodulatory effects of diabetic retinopathy patients sera. Int J Clin Pharm Res 21: 27-32.
11. Skopinski P, Skopinska-Rozewska E, Sommer E et al. (2005): The effect of some diet-derived angiogenesis inhibitors and sulindac sulfone on the ability of VEGF, bFGF and IL-18 to induce cutaneous neo-vascular response in mice. Pol J Environmental Studies 14 (suppl II): 325-329.
12. Skopinski P, Rogala E, Duda-Krol B, et al. (2005): Increased interleukin-18 content and angiogenic activity of sera from diabetic (Type 2) patients with background retinopathy. J Diabetes Complications 19: 335-338.
13. Cho ML, Jung YO, Moon YM, et al. (2006): Interleukin 18 induces the production of VEGF in RA synovial fibroblasts via AP-1-dependent pathways. Immunol Lett 103: 159-166.
14. Barcz E, Skopinska-Rozewska E, Kaminski P, et al. (2002): Angiogenic activity and IL-8 concentrations in peritoneal fluid and sera in endometriosis. Int J Gynaecol Obstet 79: 229-235.
15. Skopinski P, Szaflik J, Duda-Krol B, et al. (2004): Suppression of angiogenic activity of sera from diabetic patients with non-proliferative retinopathy by compounds of herbal origin and sulindac sulfone. Int J Mol Med 14: 707-711.
16. Skopinski P, Skopinska-Rozewska E, Sommer E et al. (2004): Inhibitory effect of complement inactivation and epigallocatechin gallate on the human serum ability to induce cutaneous neovascular reaction in mice. Bull Vet Inst Pulawy 48: 485-487.
17. Sidky YA, Auerbach R (1975): Lymphocyte-induced angiogenesis: a quantitative and sensitive assay of the graft-vs.-host reaction. J Exp Med 141: 1084-1100.
18. Skopinski P, Barcz E, Szaflik J, et al. (2006): Angiogenic activity and IL-12p40 concentration in healthy people and diabetes patients sera. Central Eur J Immunol 31: 18-21.
19. Grant MB, Afzal A, Spoerri P, et al. (2004): The role of growth factors in the pathogenesis of diabetic retinopathy. Expert Opin Investig Drugs 13: 1275-1293.
20. Knott RM (1998): Insulin-like growth factor type 1 - friend or foe? Br J Ophthalmol 82: 719-720.
21. Paques M, Massin P, Gaudric A (1997): Growth factors and diabetic retinopathy. Diabetes Metab 23: 125-30.
22. Mahmoud RA, el-Ezz SA, Hegazy AS (2004): Increased serum levels of IL-18 in patients with diabetic nephropathy. Ital J Biochem 53: 73-81.
23. Nakamura A, Shikata K, Hiramatsu M, et al. (2005): Serum IL-18 levels are associated with nephropathy and atherosclerosis in Japanese patients with type 2 diabetes. Diabetes Care 28: 2890-2895.
24. Suchanek H, Mysliwska J, Siebert J, et al. (2005): High serum IL-18 concentrations in patients with coronary artery disease and type 2 diabetes mellitus. Eur Cytokine Netw 16: 177-185.
25. Fischer CP, Perstrup LB, Bernsten A, et al. (2005): Elevated plasma IL-18 is a marker of insulin-resistance in type 2 diabetic and non-diabetic humans. Clin Immunol 117: 152-160.
26. Jung L, Skopinska-Rozewska E, Maldyk P, et al. (2006): Enoxaparine treatment enhanced angiogenic activity of mouse and human serum. Central Eur J Immunol 31: 6-10.
27. Zhang D, Bar-Eli M, Meloche S, Brodt P (2004): Dual regulation of MMP-2 expression by the type 1 insulin-like growth factor receptor: the phosphatidylinositol 3-kinase/Akt and Raf/ERK pathways transmit opposing signals. J Biol Chem 279: 19683-19690.